Comparison Chart BioLineRx Ltd. Nasdaq

Equities

Real-time Estimate Cboe BZX Other stock markets 19:30:02 06/06/2024 BST			5-day change	1st Jan Change
0.734 ^USD	+1.38%		-11.69%	-53.89%

05-30	BioLineRx Ltd Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapy Applications in Sickle Cell Disease	CI
05-28	Transcript : BioLineRx Ltd., Q1 2024 Earnings Call, May 28, 2024

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes

		Sector	Change	5d. change	1st Jan change	1-year change	5-years change	Capi.	ST	MT	LT
	BIOLINERX LTD.	Bio Therapeutic Drugs	0.00%	-11.69%	-53.89%	-54.75%	-85.85%	57.79M	-	-	-